The Pre-clinical investigation laboratory at the Curie Institute (LIP) has 25 years experience in developing patient-derived PDXs of a wide range of cancers including breast, colon, lung, ovary, uveal melanoma, retinoblastoma, Head and Neck cancers.
The Pre-clinical investigation laboratory is developing the next generation of PDX models, from drug-resistant tumors, metastatic cancer to humanized models. LIP services includes:
<ul>
<li>Preclinical pharmacology &#x26; pharmacodynamics of anti-cancer drugs</li>
<li>Identification of predictive biomarkers of response and resistance to anti-cancer agents</li>
<li>Collaboration with many national and European academics &#x26; pharmaceutical companies <a href="https://science.institut-curie.org/platforms/pre-clinical-investigation-laboratory-lip/">Read more</a></li>
</ul>
We have established a collection of heterotopic ovarian cancers PDXs.
The Pre-clinical investigation laboratory is a member of the <a href="http://www.europdx.eu">EurOPDX Consortium</a>. EurOPDX is supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 731105 <a href="https://cordis.europa.eu/project/rcn/212589_en.html">EDIReX</a>

Institut Curie - LIP - Breast Cancer